Immuneering Corporation · NASDAQ:IMRX
Immuneering — Investor Presentation (September 2025)
27 slides from Immuneering's investor presentation, September 2025
Slide 1: Keeping Cancer Patients Alive and Helping Them Thrive
Keeping Cancer Patients Alive and Helping Them Thrive September 2025 1 2025 Presentation
Slide 2: Forward-Looking Statements and Other Disclaimers
. FORWARD-LOOKING STATEMENTS AND OTHER DISCLAIMERS This presentation contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be con
Slide 3: What We Will Discuss Today
What We Will Discuss Today • Extraordinary overall survival for first-line pancreatic cancer patients treated with atebimetinib + chemo • Favorable tolerability and potential for best-in-class profile • Pushing forward: Phase 3 in first-line pancreatic cancer; new Phase 2 studies in lung cancer; Dee
Slide 4: Extraordinary Overall Survival (OS) Observed at 9 Months in First-Line Pancreatic Cancer
Extraordinary Overall Survival (OS) Observed at 9 Months in First-Line Pancreatic Cancer Atebimetinib (320 mg QD) + mGnP OS, N=34 94% 86% 6 mo. 9 mo. Atebimetinib + mGnP (320 mg atebi; N=34) 9-month OS 86% [66, 94] As of the August 26, 2025 data cutoff, the median follow-up for overall survival (OS)
Slide 5: Extraordinary Overall Survival (OS) Observed at 9 Months in First-Line Pancreatic Cancer
Extraordinary Overall Survival (OS) Observed at 9 Months in First-Line Pancreatic Cancer Atebimetinib (320 mg QD) + mGnP OS, N=34 94% 86% 9-month OS atebimetinib Standard of Care +27% + mGnP 86% [66, 94] Ph3 MPACT IMRX +39% Standard of (Gem/nab-Pac) Phase 2a Care GnP ~47% (atebi + mGnP) 67% 6 mo. 6-
Slide 6: Extraordinary Overall Survival (OS) Observed at 9 Months in First-Line Pancreatic Cancer
Extraordinary Overall Survival (OS) Observed at 9 Months in First-Line Pancreatic Cancer Atebimetinib (320 mg QD) + mGnP OS, N=34 — Ph2a IMRX (atebimetinib + mGnP) Atebimetinib + mGnP (320 mg atebi-; N=34) 9-month OS 86% [66, 94] — Ph3 NAPOLI-3 (NALIRIFOX) — Ph3 PRODIGE (FOLFIRINOX) As of the August
Slide 7: Progression-Free Survival (PFS) Supports Extraordinary Overall Survival in First-Line Pancreatic Cancer
Progression-Free Survival (PFS) Supports Extraordinary Overall Survival in First-Line Pancreatic Cancer Atebimetinib (320 mg QD) + mGnP PFS, N=34 Atebimetinib + mGnP (320 mg atebi-; N=34) 9-month PFS 53% [31, 71] 70% 6 mo. As of the August 26, 2025 data cutoff, the median 53% follow-up for overall s
Slide 8: Progression-Free Survival (PFS) Supports Extraordinary Overall Survival in First-Line Pancreatic Cancer
Progression-Free Survival (PFS) Supports Extraordinary Overall Survival in First-Line Pancreatic Cancer Atebimetinib (320 mg QD) + mGnP PFS, N=34 9-month PFS 70% atebimetinib + mGnP 53% [31, 71] Standard of Care GnP ~29% +26% 53% 6-month PFS atebimetinib 44% +24% + mGnP 70% [49, 83] 6 mo. Standard o
Slide 9: Progression-Free Survival (PFS) Supports Extraordinary Overall Survival in First-Line Pancreatic Cancer
Progression-Free Survival (PFS) Supports Extraordinary Overall Survival in First-Line Pancreatic Cancer Atebimetinib (320 mg QD) + mGnP PFS, N=34 — Ph2a IMRX (atebimetinib + mGnP) Atebimetinib + mGnP — Ph3 NAPOLI-3 (NALIRIFOX) (320 mg atebi-; N=34) — Ph3 PRODIGE (FOLFIRINOX) — Ph3 MPACT (Gem/nab-Pac
Slide 10: Overall Response Rate (ORR) and Disease Control Rate (DCR) Support Extraordinary Overall Survival
Overall Response Rate (ORR) and Disease Control Rate (DCR) Support Extraordinary Overall Survival in First-Line Pancreatic Cancer Atebimetinib + mGnP Overall Response (ORR) & Disease Control (DCR) Rates Atebimetinib + mGnP Ph 2a 1L PDAC1 ORR 39% (14/36) DCR 81% (29/36) Prior Phase 3 Benchmark Overal
Slide 11: Deepening Tumor Responses Over Time Observed
Deepening Tumor Responses Over Time Observed Atebimetinib (320 mg QD) + mGnP RECIST SLD (% change) = refractory to treatment combination (N=3, on treatment = 0) Months = stabilized with eventual or potential escape (N=6, on treatment = 1) (from screening scan) = stabilized with durable or deepening
Slide 12: Favorable Tolerability Profile in First-Line Pancreatic Cancer
Favorable Tolerability Profile in First-Line Pancreatic Cancer Safety Data for Pivotal Trials and for Atebimetinib + mGnP in 1L PDAC Gem/nab-Pac FOLFIRINOX NALIRIFOX Atebimetinib + mGnP PIVOTAL STUDY (1 MPACT; N=431) (2 PRODIGE/ACCORD 11; N=171) (3 NAPOLI 3; N=383) (320 mg atebi-; N=34) Grade ≥ 3 Gr
Slide 13: Atebimetinib + mGnP Evaluated in Older Patient Population
Atebimetinib + mGnP Evaluated in Older Patient Population IMRX Ph2a (320 mg) MPACT PRODIGE/ACCORD 11 NAPOLI 3 Characteristic Atebimetinib + mGnP Gem/nab-Pac FOLFIRINOX NALIRIFOX Trial Phase Phase 2a Phase 3 Phase 2/3 Phase 3 Patient Population Metastatic PDAC (>90%) Metastatic PDAC Metastatic PDAC M
Slide 14: Global Randomized Pivotal Trial Plan: Designed to Demonstrate Best-in-Class Profile in 1L PDAC
Global Randomized Pivotal Trial Plan: Designed to Demonstrate Best-in-Class Profile in 1L PDAC Planned Patient Population: First-line (1L) metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Primary Endpoint Atebimetinib + mGnP1 (N=180) OS • First line (1L) PDAC Secondary Endpoints R • Metastatic set
Slide 15: Projected Timeline for Phase 3 Study of Atebimetinib + mGnP in First-Line Pancreatic Cancer
Projected Timeline for Phase 3 Study of Atebimetinib + mGnP in First-Line Pancreatic Cancer Expected Q4 Regulatory First Feedback; Topline Patient Initiate Study Readout Dosed Phase 3 Trial Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2025 2026 2027 2028 2029 Projected timelines are estimat
Slide 16: Changing the paradigm for targeted therapy, to improve durability and tolerability
Changing the paradigm for targeted therapy, to improve durability and tolerability. How does atebimetinib work? 16 2025 Presentation
Slide 17: Atebimetinib goal: achieve durability by outpacing cancer
Atebimetinib goal: achieve durability by outpacing cancer Our drug candidates are Most therapies are designed designed for deep cyclic for sustained inhibition, inhibition, driving cancer to adapt and pulsing faster than cancer develop resistance; tumors can adapt; tumors shrink shrink quickly but t
Slide 18: Atebimetinib goal: achieve tolerability by outpacing cancer
Atebimetinib goal: achieve tolerability by outpacing cancer proliferative signaling Healthy Cells: Transient Signaling Time → proliferative signaling Cancer Cells: Sustained Signaling Time → Sustained Inhibition Deep Cyclic Inhibition (DCI) proliferative proliferative signaling signaling IC50 ≥ IC90
Slide 19: Atebimetinib Monotherapy Case Study Showed Durability and Tolerability with Complete Resolution of Bone Lesion
Atebimetinib Monotherapy Case Study Showed Durability and Tolerability with Complete Resolution of Bone Lesion Ongoing Phase 1 Case Study Atebimetinib Monotherapy (3L PDAC; Phase 1) (3L Metastatic PDAC) RECIST SLD • 1st Line (1L): FOLFIRINOX (BOR = PD) (% change) • 2nd Line (2L): Gem/Cis/nab-Pac (BO
Slide 20: Atebimetinib targets MEK in the MAPK pathway, designed to outpace cancer with durability and tolerability
Atebimetinib targets MEK in the MAPK pathway, designed to outpace cancer with durability and tolerability “the MAPK pathway is altered RAS or inappropriately activated in a majority of cancers” BRAF CRAF Approved MEK Atebimetinib P Inhibitors MEK P DCI MEKi Our initial focus for atebimetinib Chronic
Slide 21: Phase 1 monotherapy activity and Phase 2a combination rationale
Phase 1: Atebimetinib monotherapy showed activity, durability, and tolerability Phase 2a: Evaluating atebimetinib + mGnP in first line pancreatic cancer Molecular rationale for the combination MIA PaCa-2: Human PDAC Xenograft Copy of 125_Fig-Data: TV (mm3) - ALL groups: IMM-1-104 at 125 mpk BID Phas
Slide 22: Targeting the MAPK Pathway: Broad Relevance in Most Cancers, Expansive Opportunity
Targeting the MAPK Pathway: Broad Relevance in Most Cancers, Expansive Opportunity Pancreatic Cancer Lung Cancer Colorectal Cancer Melanoma …and many more 22 2025 Presentation
Slide 23: Extraordinary Overall Survival Observed at 9 Months With Clear Anticipated Milestones Ahead
Extraordinary Overall Survival (OS) Observed at 9 Months in First-Line Pancreatic Cancer With Clear Anticipated Milestones Ahead Atebimetinib (320 mg QD) + mGnP OS, N=34 94% Expected Expected 86% Timing Milestones 6 mo. • Regulatory feedback on 9 mo. pivotal trial plans Q4 2025 • Pending FDA feedbac
Slide 24: What We Learned Today
What We Learned Today • Extraordinary overall survival for first-line pancreatic cancer patients treated with atebimetinib + chemo • Favorable tolerability and potential for best-in-class profile • Pushing forward: Phase 3 in first-line pancreatic cancer; new Phase 2 studies in lung cancer; Deep Cyc
Slide 25: Appendix
Appendix 25 2025 Presentation
Slide 26: Extraordinary Overall Survival (OS) Observed at 9 Months in First-Line Pancreatic Cancer
Extraordinary Overall Survival (OS) Observed at 9 Months in First-Line Pancreatic Cancer Atebimetinib (320 mg QD) + mGnP OS, N=34 Atebimetinib + mGnP (320 mg atebi-; N=34) 9-month OS 86% [66, 94] As of the August 26 data cutoff, the median follow-up for overall survival (OS) was 9.0 months as estima
Slide 27: Progression-Free Survival (PFS) Supports Extraordinary Overall Survival in First-Line Pancreatic Cancer
Progression-Free Survival (PFS) Supports Extraordinary Overall Survival in First-Line Pancreatic Cancer Atebimetinib (320 mg QD) + mGnP PFS, N=34 Atebimetinib + mGnP (320 mg atebi-; N=34) 9-month PFS 53% [31, 71] As of the August 26 data cutoff, the median follow-up for overall survival (OS) was 9.0